This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (141)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Benjamin S. Wilfond, MD; Norman Fost, MD, MPH

JAMA. 1990;263(20):2777-2783.

Abstract
The primary goal of mass screening programs for cystic fibrosis carriers should be to allow people to make more informed reproductive decisions. However, previous experience with genetic screening programs, including those for phenylketonuria and sickle cell disease, have revealed complex problems including error, confusion, and stigmatization. These problems could be greater with cystic fibrosis, since more than 8 million Americans may be carriers and entrepreneurial interests can be expected to promote screening in what could become a billion-dollar industry. The present frequency of the detectable mutation (F₅₀₈), 75%, will complicate the counseling process. The sensitivity of the test to detect at-risk couples would be 56%. The cost of screening could be as much as $2.2 million for each cystic fibrosis birth avoided. Regardless of improvements in the detection rate, implementation of population screening should be delayed until pilot studies that demonstrate its safety and effectiveness are completed. While studies are in progress, preconception testing should be offered to adult relatives of cystic fibrosis patients as part of a comprehensive program following institutional review board approval for "compassionate use." The purpose of such review should be to ensure that strict standards of informed consent, education, quality control of the testing procedure, and counseling are followed. Primary care physicians who are unable to offer screening as part of such a comprehensive program should refer high-risk patients who would like to consider being tested to established centers.

(JAMA. 1990;263:2777-2783)

Author Affiliations
From the Department of Pediatrics and the Program in Medical Ethics, University of Wisconsin School of Medicine, Madison.

Footnotes
Reprint requests to Department of Pediatrics, H4/4 CSC, University of Wisconsin Children's Hospital, 600 Highland Ave, Madison, WI 53792 (Dr Wilfond).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pediatric Residents' Use of Jargon During Counseling About Newborn Genetic Screening Results
Farrell et al.
Pediatrics 2008;122:243-249.
ABSTRACT | FULL TEXT  

Content of Communication by Pediatric Residents After Newborn Genetic Screening
Farrell et al.
Pediatrics 2005;116:1492-1498.
ABSTRACT | FULL TEXT  

Initially Misleading Communication of Carrier Results After Newborn Genetic Screening
La Pean and Farrell
Pediatrics 2005;116:1499-1505.
ABSTRACT | FULL TEXT  

"Genetic Exceptionalism" in Medicine: Clarifying the Differences between Genetic and Nongenetic Tests
Green and Botkin
ANN INTERN MED 2003;138:571-575.
ABSTRACT | FULL TEXT  

Report Card on Molecular Genetic Testing: Room for Improvement?
Grody and Pyeritz
JAMA 1999;281:845-847.
FULL TEXT  

The 'new' genetics and the sociology of medical technology
Willis
Journal of Sociology 1998;34:170-183.
ABSTRACT  

Prenatal Genetic Carrier Testing Using Triple Disease Screening
Eng et al.
JAMA 1997;278:1268-1272.
ABSTRACT  

Family History and Genetic Risk Factors: Forward to the Future
Pyeritz
JAMA 1997;278:1284-1285.
ABSTRACT  

Benefits and Burdens of Genetic Carrier Identification
Williams and Schutte
West J Nurs Res 1997;19:71-81.
ABSTRACT  

Genetic Privacy
Gostin
J Law Med Ethics 1995;23:320-330.
 

General practice and new genetics: what do general practitioners know about community carrier screening for cystic fibrosis?
Boulton and Williamson
Public Understanding of Science 1995;4:255-267.
ABSTRACT  

A Qualitative Assessment of Primary Care Physicians' Perceptions about the Ethical and Social Implications of Offering Genetic Testing
Geller and Holtzman
Qual Health Res 1995;5:97-116.
ABSTRACT  

National Policy Development for the Clinical Application of Genetic Diagnostic Technologies: Lessons From Cystic Fibrosis
Wilfond and Nolan
JAMA 1993;270:2948-2954.
ABSTRACT  

Incorporation of Genetics in Primary Care Practice: Will Physicians Do the Counseling and Will They Be Directive?
Geller et al.
Arch Fam Med 1993;2:1119-1125.
ABSTRACT  

Genetic Diagnosis and Treatment: Ethical Considerations
Fost
Arch Pediatr Adolesc Med 1993;147:1190-1195.
ABSTRACT  

Cystic Fibrosis and Heterozygote Fitness
Johnson
JAMA 1990;264:2867-2867.
ABSTRACT  

Preconception Care: Risk Reduction and Health Promotion in Preparation for Pregnancy
Jack and Culpepper
JAMA 1990;264:1147-1149.
ABSTRACT